tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals Issues New Equity Securities

Story Highlights
Telix Pharmaceuticals Issues New Equity Securities

Confident Investing Starts Here:

The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).

Telix Pharmaceuticals Limited has announced the issuance of new ordinary fully paid securities, totaling 210,000 shares, on two separate dates in May 2025. This move is part of the company’s strategy to manage its equity and potentially strengthen its financial position, which may have implications for its market performance and stakeholder interests.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. The company targets the oncology market, providing innovative solutions for cancer diagnosis and treatment.

Average Trading Volume: 1,968,807

Technical Sentiment Signal: Buy

Current Market Cap: A$8.64B

For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1